Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models

Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models

Repulsive guidance molecule A (RGMa) is a potent inhibitor of axonal growth and a regulator of neuronal cell death. It is up-regulated following neuronal injury and accumulates in chronic neurodegenerative diseases. Neutralizing RGMa has the potential to promote neuroregeneration and neuroprotection...

Full description

Bibliographic Details
Main Authors: Lili Huang, Emma Fung, Sahana Bose, Andreas Popp, Preethne Böser, John Memmott, Yuliya A. Kutskova, Renee Miller, Edit Tarcsa, Corinna Klein, Geertruida M. Veldman, Bernhard K. Mueller, Yi-Fang Cui
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:Neurobiology of Disease
Subjects:
RGMa
Elezanumab
ABT-555
ABT-207
Monoclonal antibody
BMP
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996121002412

Similar Items

Similar Items